MedTrace Logo

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer

NCT00160069 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2014-12-04

No results posted yet for this study

Summary

Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.

Conditions

  • Carcinoma, Non Small Cell Lung

Interventions

DRUG

Sagopilone (BAY86-5302, ZK 219477)

16 mg/m2, 3-hour infusion, every 3 weeks

DRUG

Sagopilone (BAY86-5302, ZK 219477)

22 mg/m2, 30-min infusion, every 3 weeks

DRUG

Sagopilone (BAY86-5302, ZK 219477)

22 mg/m2, 3-hour infusion, every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-04-30
Completion
2009-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160069 on ClinicalTrials.gov